"Our infection inhibition assay results clearly indicate that CBDA and CBGA are both able to block cell entry by SARS-CoV-2. The concentrations needed to block

"Our infection inhibition assay results clearly indicate that CBDA and CBGA are both able to block cell entry by SARS-CoV-2. The concentrations needed to block infection by 50% of viruses is high but might be clinically achievable. For example, CBDA administered orally to human volunteers at 0.063 mg/kg showed greater bioavailability than CBD and produced maximum plasma concentrations of 0.21 μM. (32) In beagle dogs, oral administration of CBDA at 1 mg/kg was well tolerated, was 2-fold more bioavailable than CBD, and produced serum levels up to 1.42 μM. (41) Although no data on the bioavailability of CBGA are yet available, the data for CBDA suggest that μM plasma and serum concentrations for CBGA should also be possible."